Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that virtually the same percentage of surveyed rheumatologists selected Amgen/Pfizer/Takeda's Enbrel and Abbott/Eisai's Humira as the most efficacious agent for the treatment of rheumatoid arthritis.
Virtually the same percentage of surveyed rheumatologists selected Enbrel and Humira as the most efficacious agent for the treatment of rheumatoid arthritis